公开(公告)号：US20160274116A1

公开(公告)日：2016-09-22

申请号：US14919388

申请日：2015-10-21

Applicant: Genentech, Inc.

Inventor： Siminder ATWAL ,  Jo-Anne HONGO ,  Mark LACKNER ,  Elizabeth PUNNOOSE ,  Bonnee RUBINFELD ,  Rajesh VIJ

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  C07K16/3069 ,  C12N5/0693 ,  C12Y116/01 ,  C12Y301/03048 ,  G01N33/57492 ,  G01N2333/4742 ,  G01N2333/70596 ,  G01N2333/90287 ,  G01N2333/916 ,  G01N2800/52

Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.

公开(公告)号：US20230064677A1

公开(公告)日：2023-03-02

申请号：US17816986

申请日：2022-08-02

Applicant: Genentech, Inc.

Inventor： Mark LACKNER ,  Daniel Maslyar ,  Yulei Wang ,  Walter Darbonne ,  Eric Humke

IPC: C07K16/30 ,  A61K47/65 ,  G01N33/574 ,  C07K16/28 ,  A61K47/68 ,  A61K31/7048 ,  A61P35/00 ,  A61K31/22 ,  A61K39/00

Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.

公开(公告)号：US20190233538A1

公开(公告)日：2019-08-01

申请号：US16239663

申请日：2019-01-04

Applicant: Genentech, Inc.

Inventor： Mark LACKNER ,  Daniel MASLYAR ,  Yulei WANG ,  Walter DARBONNE ,  Eric HUMKE

IPC: C07K16/30 ,  G01N33/574 ,  C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K47/65 ,  A61K31/22 ,  A61K31/7048

CPC classification number: C07K16/3092 ,  A61K31/22 ,  A61K31/7048 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6859 ,  A61K47/6869 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2896 ,  C07K2317/94 ,  G01N33/57407 ,  G01N33/57449 ,  G01N33/57484

Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.